Archives: Speakers

Stefano Pistoni, Senior Manager, Business Development in Wine, Spirits & Beverage, EMEIA region at UPM Raflatac. With more than 25 years of experience in the packaging industry, in his role he sees himself as a privileged spectator of the packaging and design community. Stefano collaborates with the global wine and spirits brands and most prestigious packaging design agencies. Over the years he has collaborated in several projects related to sustainability and circular economy, such as ”Project RafCycle”, and he is collaborating with “Circular Wine” platform in Italy, and IED Istituto Europeo del Design.

Hannah currently leads J.P. Morgan Payments’ Marketing Campaign Strategy for the EMEA region. Equal parts strategist and creative, much of her time is spent thinking about the future of Payments, from the perspective of end users, merchants, and processors, and conveying that in a digestible format for all audiences, regardless of their Payments acumen.

Passionate about Gender equity, Hannah Co-Chaired the Gender Network at Barclays, where she founded the Barclays Career Kickstarter, an initiative designed to dispel the misconception of an ‘ideal candidate’ in early careers. The scheme provides resources and advice to students, largely targeting those not yet considering a career in Financial Services, aiming to increase black, female and non-STEM graduate representation. At J.P. Morgan Payments, Hannah has remained passionate about early careers, currently leading the London Payments Apprenticeship programme.

Dubbed One to Watch by Brummell Magazine, Hannah is part of a new generation of Payments professionals driving the next phase of change in our industry.

Dr. Moser is an oncologist who has worked as a clinician and academic researcher for over 20 years and specialized in drug development for the past 10. She completed her PhD in Statistics working at the EORTC in Brussels and has led many multi-institutional trials and related cancer survivorship projects since. After completing her MBA at MIT Sloan School of Management (2017), she moved to the US and shifted focus from academic to commercial research. She has helped drive the clinical pipeline from early to late stage in larger (Elekta, Roche) and smaller (Augmenix, Kaiku, Artidis, Galera Therapeutics) companies and commercialization of several products including the post-marketing performance. Dr. Moser has obtained extensive clinical operational and regulatory experience dealing with different stakeholders (academic, industry, policymakers and patient advocates). Dr. Moser has helped direct the investment in private owned drug-development, as well as new cancer centers worldwide and was instrumental in launching Portugal’s National Cancer Institute. Dr. Moser previously served as the Vice President for Clinical Development for Galera Therapeutics, with who she went IPO in 2019 and SVP Clinical Strategy for ELEKTA Inc, a global radiation oncology device vendor (2017-2018). She founded Nanocan Therapeutics Corporation in 2020 and serves as the Chief Scientific Officer. Working with different academic groups she obtained over 5M of NIH-STTR awards to drive preclinical research and opening first in-human trials.

Desmond Cabrera serves as Executive Director, Cell & Gene Therapies and brings over 15 years of experience in the CRO industry. In his current position, Desmond is the Global Therapeutic Operations Lead for Allucent’s Cell and Gene Portfolio in which he leads the strategy and team executing trials for sponsors who are developing CAG Therapies.

Desmond has gained extensive experience in the execution and management of clinical trials in all phases throughout his career and has worked at large CROs including ICON, IQVIA, Labcorp, and Parexel. He has led multinational teams and projects overseeing trials for oncology, pediatric, CNS and large-scale cardiovascular studies that involved 1,000+ sites and 25,000 patients. Desmond has overseen several early phase cell and gene therapy (CGT) projects involving feasibility and safety assessments, first-in-human studies, and dose escalation and expansion for oncology indications including breast and lung cancer, acute myeloid leukemia, and myelodysplastic syndrome.